



Media Release

PlantForm Corporation signs licensing agreement with the University of Guelph .

Guelph, ON (January 29, 2009) – PlantForm Corporation announced today that it has signed an agreement with the University of Guelph to license technology developed at the University which it intends to commercialize. The technology was developed over a number of years in the laboratory of Dr. Chris Hall. Dr. Hall is the Canada Research Chair in Recombinant Antibody Technology at the University.

"This is potentially revolutionary," says Dr. Donald Stewart, CEO of **PlantForm** "with the University's proprietary technology, we will create high-quality pharmaceuticals for both the western world and also for developing countries," adds Dr. Stewart: "there is wonderful irony in using the tobacco plant to treat cancer."

PlantForm Corporation:

PlantForm is a biotechnology company that uses new platform technology to quickly produce vaccines and antibodies in tobacco plants. Tobacco grows rapidly and is proving to be a faster and cheaper way to produce these pharmaceuticals. The company's first product under development is a biosimilar (or generic) version of the breast cancer drug Herceptin.

Dr. Stewart is the former Director of Research at Cangene Corporation, Canada's largest publicly traded biotechnology company. **PlantForm** combines a top level board and management team with state-of-the-art research developed in the laboratory of Dr. Chris Hall at the University of Guelph. In October, 2008, **PlantForm's** potential as an investment opportunity was recognized as the company was selected in the Lifesciences category as a winner in Canada's Top 10TM Competition.

PLANTFORM gratefully acknowledges the support of the Ontario Centres For Excellence's Market Readiness Program.

University of Guelph:

Prof. Kevin Hall, the Vice-President Research at the University of Guelph, said: "This is a tremendous example of how innovative research and collaboration can create capacity to solve real-life problems and improve the quality of people's lives. It also demonstrates the importance and the strength of our partnerships with OMAFRA in supporting groundbreaking advances."

For information visit www.plantformcorp.com or contact Dr. Don Stewart, CEO, PlantForm Corporation; (416) 452 7242, don.stewart@plantformcorp.com.